Cargando…
The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (biocompatible) peritoneal dialysis (PD) solutions significantly delayed anuria and reduced peritonitis rates compared with conventional solutions. This article reports a secondary outcome analysis of the...
Autores principales: | Johnson, David W., Brown, Fiona G., Clarke, Margaret, Boudville, Neil, Elias, Tony J., Foo, Marjorie W.Y., Jones, Bernard, Kulkarni, Hemant, Langham, Robyn, Ranganathan, Dwarakanathan, Schollum, John, Suranyi, Michael G., Tan, Seng H., Voss, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520083/ https://www.ncbi.nlm.nih.gov/pubmed/22859794 http://dx.doi.org/10.1093/ndt/gfs314 |
Ejemplares similares
-
Rationale and design of the balANZ trial: A randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function
por: Johnson, David W, et al.
Publicado: (2010) -
Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study
por: Ranganathan, Dwarakanathan, et al.
Publicado: (2009) -
Calcific Uremic Arteriolopathy in Peritoneal Dialysis Populations
por: New, Nicholas, et al.
Publicado: (2011) -
Incremental Versus Standard (Full-Dose) Peritoneal Dialysis
por: Cheetham, Melissa S., et al.
Publicado: (2021) -
Association of Peritonitis With Cardiovascular Mortality Over Time in the Peritoneal Dialysis Population: An Australia and New Zealand Dialysis and Transplant Registry Study
por: Cheikh Hassan, Hicham I., et al.
Publicado: (2022)